10/5/6618

Docket No.: KUK-06101

IAP20 ROBA FOTTETO 21 APR 2006

## CERTIFICATION

I, the below named translator, hereby declare that: my name and post office address are as stated below; that I am knowledgeable in the English and German languages, and that I believe that the attached text is a true and complete translation of PCT/EP2004/011788, filed with the European Patent Office on October 19, 2004.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Hollywood, Florida

Rebekka Pierre

April 21, 2006

Lerner Greenberg Stemer LLP P.O. Box 2480 Hollywood, FL 33022-2480

Tel.: (954) 925-1100 Fax.: (954) 925-1101

14P2 ROSCI 61/910 21 APR 2006

Process and Bioreactor for the Cultivation and Stimulation of Three-dimensional, Vitally and Mechanically Resistant

Cell-Transplants

4

1

2

- 5 The invention relates to a process and an arrangement for
- 6 the cultivation of three-dimensional, vital and
- 7 mechanically-resistant cell cultures, preferably cartilage-
- 8 cell constructs which can hereby be cultivated and
- 9 stimulated in a locked mini-bioreactor simultaneously,
- 10 consecutively or within a time-controlled process according
- 11 to GMP guidelines. These transplants which are cultivated in
- 12 this manner are then available as replacement tissue
- 13 material for the therapy of connective and supporting tissue
- 14 defects, direct joint traumas, rheumatism and degenerative
- 15 joint disease, for example and can with an arthrosis of the
- 16 knee joint present an alternative to the conventional
- 17 (operative) therapy approaches, such as micro fracturing or
- 18 drill perforation, for example.

19

- 20 With Tissue Engineering which above all concerns itself with
- 21 the in-vitro reproduction of endogenic, so-called autologous
- 22 cell material, one attempts to cultivate functional
- 23 replacement cell and tissue structures which could be
- 24 inserted into the defective tissue during a transplantation
- 25 phase.

26

- 27 To this end, cell cultures (e.g. joint cartilage cells) are
- 28 routinely reproduced in the laboratory. The actual
- 29 reproduction of these cells (e.g. chondrocytes) takes place
- 30 in a monolayer culture on the bottom of a coated cell
- 31 culture flask or dish in accordance with standard protocols
- 32 which also include the addition of tissue-related growth
- 33 factors, mediators and inductors.

- 35 The objective of these additive factors is for example, the
- 36 stimulation of the special ability which cartilage cells

- 1 have to synthesise a sufficient number of extracellular
- 2 matrix components (ECM), in order to achieve a mass ratio of
- 3 1% chondrocytes to 99% extracellular matrix components
- 4 during the in-vitro reproduction, this being the ratio which
- 5 exists in functional joint cartilage (Stockwell RA: The cell
- 6 density of human articular and costal cartilage. J Anat.
- 7 1967;101(4):753-763; Hamerman D, Schubert M: Diarthrodial
- 8 joints, an essay. Amer J Med. 1962;33:555-590).
- 9 As this does not appear to be possible by simply adding
- 10 medium supplements, an attempt is made to affect or
- 11 stimulate these cartilage cells by applying various ways and
- 12 means in order to render it possible to cultivate suitable
- 13 replacement autologous (hyaline) cartilage with a high
- 14 degree of differentiation in the laboratory.

- 16 The described reproduction of cell cultures and the
- 17 cultivation of replacement tissue structures has numerous
- 18 disadvantages.

19

- 20 This passive cultivation of cartilage cell cultures in a
- 21 two-dimensional surface culture on a simple culture dish
- 22 which is coated with a culture medium does not produce an
- 23 active stimulation of the cartilage cells which are capable
- 24 of differentiation.

- 26 From Minuth, W. W., Kloth S., Aigner J., Steiner P.:
- 27 MINUSHEET-Perfusionskultur: Stimulierung eines
- 28 gewebetypischen Milieus. Bioscope 1995; 4:20-25 a concept is
- 29 known which attempts to avoid this disadvantage in that one
- 30 places the cell material taken from the patient in an
- 31 artificial carrier structure which has biophysical
- 32 properties which are similar to those of the cartilage
- 33 tissue and which permits a network-type connection between
- 34 the multilayer arranged cells and which then carries out a
- 35 perfusion cultivation in a suitable bioreactor. Numerous
- 36 experiments show an increased cell differentiation

- 1 capability as a result of an increase in synthesized ECM
- 2 which results from this three-dimensional cultivation of
- 3 chondrocytes in the most differentiated biocompatible and
- 4 bio absorbable matrixes, e.g. the hydrogels, alginates,
- 5 agaroses (Benya and Shaffer: Dedifferentiated chondrocytes
- 6 reexpress the differentiated collagen phenotype when
- 7 cultured in agarose gels. Cell. 1982;30:215-224.) of various
- 8 concentrations.

- 10 This spatial dimension which is thereby created therefore
- 11 simulates the original ratios of the chondrocytes in living
- 12 tissue such as in knee and hip joints, for example and
- 13 therefore represents an advantageous adaptation of in-vivo
- 14 situations.

15

- 16 With the adherent surface cultivation of the cells, the
- 17 satisfactory supply of medium supplements is relatively
- 18 simple as these cultures are situated immediately on or
- 19 under the cells respectively, thereby permitting an
- 20 unimpaired material exchange via diffusion.

21

- 22 Contrary to this, when using three-dimensional matrixes with
- 23 imbedded cells in a static cultivation schema, it comes to
- 24 the formation of concentration inclines or gradients which
- 25 can limit the transportation of the material in medial
- 26 construct regions, thereby having a negative effect on the
- 27 optimal culture offer for the cell layers.

28

- 29 This impairment during the cultivation of cell material in
- 30 spatial carrier matrix is counteracted by the induction of
- 31 medium perfusion or transfusion through the construct.

- 33 This active process through this carrier structure ensures a
- 34 homogenous nutrient supply in the cells and results in a
- 35 continuous metabolite removal of the chondrocytes. In
- 36 addition, the dynamic cultivation schema guarantees a higher

```
gas entry and mechanically stimulates the cell layers
    subject to the selected medium perfusion flow resulting in a
 2
    shearing force in \mu Pa. (Raimondi, M. T., F. Boschetti, et
    al.: Mechanobiology of engineered cartilage cultured under a
    quantified fluid-dynamic environment. Biomechan Model
 5
    Mechanobiol. 2002;1:69 - 82)
 7
    An additional disadvantage with the reproduction of cells
 8
    and a transplant results from the fact that the "cell
    culture flask" is not absolutely sterile. Even routine tasks
10
    such as changing the media, seeding the cell and even the
11
12
    harvesting of it result in a risk of the cell culture in it
    being infected, as the corresponding culture vessels have to
13
    be opened and the working in a laminar flow workbench does
14
    not enable the 100% sterility of the working environment
15
    within the meaning of the "Basic Rules of the World Health
16
    Organisation for the Manufacturing of Pharmaceutical
17
    Products and the Assurance of their Quality " (Good
18
    Manufacturing Practice - WHO directive) to be guaranteed.
19
20
21
    Furthermore, this passive system does not permit a maximum
   gas exchange through the diffusion-permeable cover and
22
   between the culture media and the cell layer on the bottom.
23
    In order to avoid these disadvantages of the culture flask,
24
   one has in recent years increasingly accelerated the
25
   development of automated, self-contained bioreactor systems
26
   for the generation of replacement tissue structures. They
27
   can then (Freed und Vunjak-Novakovic: Microgravity tissue
28
   engineering. In Vitro Cell Dev Biol Anim. 1997;33:381-385)
29
   offer the advantage of sterile, controllable cultivation and
30
   stimulation of three-dimensional transplants. By combining
31
   the Tissue Engineering with the possibilities provided by
32
   process technology and biotechnology, the steering and
33
   control of selected cultivation parameters such as the
34
   gassing with CO_2 or O_2 respectively, temperature control, the
35
   exchanging of culture media, the taking of samples etc. in
36
```

the bioreactor system are rendered possible. (Obradovic, Carrier, Vunjak-Novakovic and Freed: Gas exchange is 2 essential for bioreactor cultivation of tissue engineered cartilage. Biotechnol Bioeng. 1999;63:197-205). 5 6 When designing bioreactors, a well thought-out system must 7 always be created, in which it is possible to regulate the processes by artificial means. When it comes to cultivating a 8 particular tissue, the bioreactor system must be able to 9 reproduce the physiological conditions and processes in-vivo 10 as accurately as possible. All of the bioreactor systems work 11 on the cultivated material with at least one kind of 12 mechanical stimulation. 13 14 The lining of the positive features of a controlled 15 bioreactor cultivation of autologous replacement tissue 16 materials in a biogenous matrix under perfusion stimulation 17 with a culture medium therefore represents the logical 18 19 consequence of guaranteeing automated sterile or GMP-20 suitable transplant cultivation for the cultivation vital cartilage cells for example, with an increased ECM-synthesis 21 performance. 22 23 24 A perfusion reactor is known from DE 4306661A1 and from 25 Sittinger M, Bujia J, Minuth WW, Hammer C, Burmester GR: Engineering of cartilage tissue using bioresorbable polymer 26 carriers in perfusion culture. Biomaterials. 1994;15(6):451-27 456, by which the cells are embedded in a polymer layer and 28 is additionally encased in an agerose capsule. An artificial 29 culture media flows through the cylindrical glass reactor 30 with a flow rate of 0.016 ml/min. The reactor itself is 31 situated in a corresponding tissue incubator with 32 standardised conditions. Sterile filters on the culture 33 medium depot enable a gas exchange to take place with the 34

outside environment.

Continuative experiments carried out with this type of reactor by Bujia J, Rotter N, Minuth W, Burmester G, Hammer C, Sittinger M: Cultivation of human cartilage tissue in a 3-dimensional perfusion culture chamber: characterization of collagen synthesis. Laryngorhinootologie. 1995;74(9): 559-563 und Kreklau B, Sittinger M, Mensing MB, Voigt C, Berger G, Burmester GR, Rahmanzadeh R, Gross U: Tissue engineering 7 of biphasic joint cartilage transplants. Biomaterials. 8 9 1999;20(18):1743-1749 used co-polymer tissues of 10 vicryldiaxonon layers and polydioxanon layers, which have 11 12 been soaked in Poly-L-Lysine or collagen fibres of type II. Human chondrocytes are imbedded in these layers and 13 cultivated under perfusion for a period of two weeks. Under 14 use of a two-phase model of a co-polymer, one polyglycolic 15 acid and a poly-L-lactic acids (Ethicon), which was attached 16 to a calcium-carbonate product, the period was extended to 17 70 days. 18 19 An additional system which is very similar to the above 20 perfusion bioreactor was constructed by Mizuno S, Allemann F, 21 Glowacki J: Effects of medium perfusion on matrix production 22 23 by bovine chondrocytes in three-dimensional collagen sponges. J Biomed Mater Res. 2001;56(3):368-375. Contrary to 24 the reactor which has already been described, this has a 25 closed area for the artificial culture media. The main part 26 of the cultivated material is situated in a cylindrical 27 glass column which is 1 cm wide and 10 cm long. The column is 28 filled with numerous cell/polymer frameworks, each having a 29 size of  $7 \times 15$  mm, these not being additionally encapsulated. 30 The artificial culture medium is led from a depot through the 31 column and the complete system at a speed of 300  $\mu$ l/min. This 32

system was used to examine bovine chondrocyte frames in

during a cultivation period of 15 days.

collagen sponges with regard to their reaction to perfusion

35 36

33

```
A bioreactor device is also known from the US-patent
    5,928,945 in which the adherent cartilage cells are
    subjected to defined flows or shearing force in a growth
    chamber which resulted in the detection of an increased
    collagen type II synthesis.
 6
    Parallel to the development of perfusion bioreactors,
 7
    research groups concerned themselves with the design of
   bioreactors which exercise diverse mechanical load processes
10
    in explants, cell samples or cell/polymer frames. When
    constructing bioreactors for the stimulation of cartilage
11
    cells, their design orients itself to the implementation of
12
   mechanical plungers, etc, as these apply uniaxial pressure
13
   to cartilage transplants in order to imitate the most
14
    important form of load applied to human cartilage tissue.
15
   Many of these pressure systems have great design
16
   similarities.
17
18
   The pressure chamber of a system developed by Steinmeyer J,
19
   Torzilli PA, Burton-Wurster N, Lust G: A new pressure
20
21
   chamber to study the biosynthetic response of articular
   cartilage to mechanical loading. Res Exp Med (Berl).
22
   1993,193(3):137-142 comprising a titanium housing which is
23
   coated by a polyethylene layer on the inside. The experiment
24
   sample with a maximum diameter of 10 mm can be placed on the
25
   floor of the chamber and covered with around 7 ml of an
26
27
   artificial culture media. As the model does not have an
   artificial culture medium perfusion system, only pressure
28
   generations in phases with short cultivation times are
29
   possible. The load system which exercises the corresponding
30
   pressure on the experiment sample comprises a porous pressure
31
32
   crucible which leads through the chamber lock and is either
   moved by means of simple weights or an air cylinder with
33
   pressure cylinder which is mounted above the chamber.
34
35
   The system published by Lee DA, Bader DL: Compressive
36
```

- 1 strains at physiological frequencies influence the
- 2 metabolism of chondrocytes seeded in agarose. J Orthop Res.
- 3 1997;15(2):181-188 which is set in motion by a drive is
- 4 capable of being able to exercise pressure on 24 test
- 5 samples simultaneously. The drive is mounted on a frame
- 6 which leads around the incubator and transfers the force
- 7 down to the loading plate inside the sterile box. The steel
- 8 loading plate has 24 steel bolts with a Plexiglas
- 9 indentation with a diameter of 11 mm. The drive provides
- 10 various loads which depend on the degree of deformation.
- 11 This system is used for the cultivation of bovine
- 12 chondrocyte/agarose frames for a period of two days. Static
- and additional cyclic loads (0.3 3 Hz) with a maximum
- 14 tension amplitude of 15 % are generated.

- 16 The disadvantage of numerous pressure stimulation reactors
- 17 is that the cell culture constructs cannot be perfused with
- 18 a culture media during a pressure load so that the effect of
- 19 a multiple cell stimulation cannot be tested. Furthermore,
- 20 this lack of culture supply is opposed by an optimal
- 21 metabolism exchange and the maximum synthesis of
- 22 extracellular matrix components in cartilage cells, for
- 23 example.

24

- 25 Pressure and perfusion systems such as those which are
- 26 described in the US-patent 6,060,306 and the DE-patent 198
- 27 08 055 enable a simultaneous multiple stimulation with
- 28 parameters such as perfusion flow, the resulting induced
- 29 shearing forces and an uniaxial pressure load.

- 31 The disadvantage of reactors which enable a pressure
- 32 stimulation to take place is above all that they necessitate
- 33 the entering of the bioreactor space which preferentially
- 34 contains an autologous transplant by pressure mediators,
- 35 mainly plungers and pistons, etc. which are driven by
- 36 servomotors, or similar and that a defined pressure load is

- 1 then applied to the cell construct. The insertion of these
- 2 pressure applicators into the sterile system renders the
- 3 designing of self-contained pressure application reactors
- 4 extremely difficult so that these systems are of an
- 5 increased complexity. A usage of the (potentially non-
- 6 sterile) systems is therefore only given in basic research
- 7 as an application of these devices and process in the
- 8 medical sector contradicts parts of the directives in the
- 9 existing Medical Preparations Act.

- 11 All of the bioreactor apparatuses used for the cultivation
- 12 and stimulation of replacement autologous tissue structures
- 13 therefore serve the WHO Good Manufacturing Practice
- 14 Directive ("Basic Rules for the Manufacturing of
- 15 Pharmaceutical Products and the Securing of their Quality")
- 16 and the German Pharmaceuticals Act (Arzneimittelgesetz)
- 17 (AMG), the "Pharmaceutical Inspections Convention" and GMP-
- 18 Directive 91/356/EEC. The risk of an infection or the
- 19 impossibility of it being possible to fully guarantee the
- 20 sterility of the systems therefore constitutes no grounds
- 21 for the issuing of a manufacturing license pursuant to
- 22 Section 13 AMG.

23

- 24 The task of the invention is the creation of a process and a
- 25 bioreactor for the manufacturing of three-dimensional, vital
- 26 and mechanically-resistant cell cultures, by which they can
- 27 be cultivated and stimulated within a short time of each
- 28 other or simultaneously. The bioreactor should permit GMP-
- 29 conform transplant cultivation under guaranteed sterile
- 30 conditions.

31

- 32 The invention fulfils the task with the process described in
- 33 Claim 1 and the bioreactor described in Claim 13.
- 34 Advantageous forms of the process are described in Claims 2-
- 35 12; Claims 14-57 describe other forms of the bioreactor.

- 1 The invented process and the invented bioreactor combines
- 2 the cultivation and stimulation of GMP-conform manufactured,
- 3 three-dimensional vital and mechanically-resistant cell
- 4 cultures, preferably cartilage cell constructs, in a single
- 5 reactor. Hereby, the stimulation and cultivation can take
- 6 place simultaneously, consecutively or in accordance with a
- 7 time-controlled process. The transplants cultivated in this
- 8 manner are available as replacement tissue material for the
- 9 therapy of connective and supporting tissue defects, direct
- 10 joint traumas, rheumatism and degenerative joint disease,
- 11 for example.

- 13 The fundamental characteristic feature of the invented
- 14 process and the invented bioreactor is that a transplant is
- 15 in a self-contained reactor chamber which can be subjected
- 16 to in-vivo-adaptive stimulus in many regards. This includes
- 17 the perfusion of the spatial culture construct with a
- 18 conditioned culture media which evokes organotypical
- 19 shearing forces on the cell membranes and additionally
- 20 permit an increased metabolic exchange to take place. A
- 21 magnetic, piston-like pressure stamp which acts as a load
- 22 applicator to the cell culture is situated above the
- 23 transplant in this self-contained bioreactor. The stamp is
- 24 controlled by the bioreactor chamber in a contactless form,
- 25 the tissue transplant being subjected to directed uniaxial
- 26 pressure stimulation. The contactless controlling of the
- 27 mini-actuator is carried out by externally arranged control
- 28 magnets whose directed (electro-)magnetic filed brings about
- 29 a change of the stamp position within the bioreactor,
- 30 resulting in an organotypical dynamic or static pressure
- 31 stimulation, respectively.

- 33 The process and the bioreactor have the advantage which has
- 34 already been described that a stimulation of the cell
- 35 cultures can also take place during cultivation. The
- 36 cultivation or regeneration of connective and supporting

```
tissue structures and functional tissue systems (cartilage,
    bones, etc.) are especially possible.
 3
    When used in a sterile process, the apparatus enables cell
 4
    transplants to be cultivated which are characterised in that
 5
 6
    they are especially synchronously perfused and pressure-
    loaded, this resulting in an increased production of matrix
 7
    components (e.g. cartilage cell cultures). Due to its degree
 8
    of automation, this device minimises the number of stages,
    thereby reducing the risk of infecting the cell culture. The
10
    automated cultivation and stimulation of the transplants
11
    also guarantees defined and reproducible process cycles. Due
12
    to the design characteristics of the invented bioreactor, a
13
    self-contained bioreactor circulation is guaranteed and this
14
   therefore enables a stringent autologous cultivation or
15
    stimulation of replacement tissue structures under adherence
16
17
    to the GMP-directives.
18
   An additional field of use of the bioreactor is the
19
   pharmaceutical active ingredient testing for the
20
   characterization of proliferation and differentiation-
21
    relevant ingredients or ingredient combinations on
22
23
   transplants.
24
   An explanation of the invented process and the invented
25
   bioreactor now follows execution examples. The corresponding
26
27
   illustrations show:
28
29
   Fig. 1:
             Process for manufacturing transplants
30
   Fig. 2:
             GMP-Bioreactor system schema
   Fig. 3:
31
             Single-chamber bioreactor schema
   Fig. 4:
32
             Double-chamber bioreactor schema
33
   Fig. 5:
             Design and form of executions of the mini
34
             actuator
35
   Fig. 6:
             Schema showing the construct manufacture and
```

seeding of the construct in the bioreactor

```
Fig. 7:
             Schema showing the technical equipment for
 2
              construct perfusion and media blending in a
 3
              single-chamber reactor
 4
              Schema showing the technical equipment for
 5
              construct perfusion and media blending in a
              double-chamber reactor
 6
 7
              Schema showing the fixation of the transplant in
 8
    Fig. 9:
              the bioreactor
 9
    Fig. 10: Magnet systems for controlling the mini actuator
10
              Schema showing the stimulation in the double-
11
    Fig. 11:
12
              chamber reactor
13
   Example 1
14
15
    Process for manufacturing transplants
16
   Figure 1 shows the use of the bioreactor for the synchronous
17
   cultivation and stimulation of three-dimensional cell
18
   transplants, taking the cartilage tissue transplantation as
19
20
   an example.
21
   To this end, the patient first of all (I) as healthy cell
22
   material (e.g. articular cartilage) and blood taken from him
23
   by minimal invasive means. The attained cells are separated
24
   and counted under enzymatic digestion, they then being
25
   either sown out in monolayer flasks (II) according to
26
   standard tissue engineering methods, where they multiply in
27
   a stringently analogous manner or they are immediately used
28
   for the manufacturing of the construct (III). Hereby, the
29
   cells are added top a three-dimensional transplant structure
30
   of biocompatible or absorbable carrier materials (e.g.
31
   hydrogels, agaroses, collagens, hydroxylapatites, polymer
32
   complexes etc.). The suspended cells (e.g. chondrocytes) are
33
34
   mixed with the biogenic support structure (e.g. agarose),
   placed in a seeding piston and hardened into a cylindrical
35
36
   transplant form, for example (e.g. cartilage-agarose-
```

matrix). This in-vivo adaptive, three-dimensional structure especially results in a (re-)differentiation and resulting synthesis of tissue-typical substances and matrix components (e.g. collagens, proteoglycane) in connective and supporting 4 5 tissue cells (e.g. chondrocytes). 6 This seeding piston with the spatial cell transplant inside 7 it is inserted into the bioreactor (IV), the transplant then 8 being pressed out and positioned in the bioreactor. The GMPsuitable cultivation and stimulation of this cell construct 10 takes place in the newly developed bioreactor apparatus (V) 11 12 GMP-conform simultaneously, consecutively or timecontrolled. During this phase, the cell transplant can be 13 caused to create an increased differentiation and expression 14 of organotypical markers (stimuli such as shearing force, 15 perfusion, deformation, mechanical load) by means of this 16 multiple in-vivo-similar stimulation. 17 18 A highly-vital, matrix-rich cell culture construct 19 regenerates in the bioreactor after a short amount of time. 20 This autologous transplant is removed (VI), adapted to the 21 geometry of the tissue defect if necessary and subsequently 22 transplanted into the defective connective or supporting 23 24 tissue. 25 26 Example 2 Bioreactor system schema 27 28 Figure 2 illustrates a form of execution of the bioreactor 29 system (with the double-chamber bioreactor) for the 30 autologous cultivation and multiple stimulation of cell 31 transplants in a self-contained reactor structure with a 32 GMP-conform process method.

34

- In this execution example, the complete equipment for 35
- guaranteeing an optimal temperature, air humidity and 36

composition is situated in a temperature-controlled and gasregulated incubator. A separate design is also possible, in 2 that the bioreactor 1 and the medium are situated in the incubator, the other technical components being situated 5 outside the incubator. 6 7 The bioreactor 1 itself and the components used therein are biologically and chemically inert and can be treated by 8 9 autoclave. Furthermore, the bioreactor carcass and the screw-on cover are of materials which are either non-10 magnetic (e.g. synthetic materials) or weak-magnetic (e.g. 11 vanadium-4-steel). 12 13 The culture medium is fed to the bioreactor 1 after being taken from the medium reservoir 2 and passing through the 14 hose system 4 with the 3-way valve 6 and the 4-way valve 7 15 by means of the circulation pump 5. This culture medium can 16 be enriched with autologous additive factors taken from the 17 18 supplement reservoir 3 (growth factors, mediators, etc.) which were obtained from the patient's blood. The medium is 19 added to bioreactor 1 and therefore the transplant 11 in a 20 21 batch, fed-batch or continuous process. 22 23 When the circulation is closed, the medium then enters the 24 medium reservoir 2 via hose system 4, the reservoir being equipped with measuring probes for controlling the 25 26 physicochemical parameters, e.g. pH, pCO2 and pO2. If the medium is seen to be used, it can be drained off into an 27 external locked waste vessel via hose system 4. In both 28 29 cases there is the possibility of deviating a sterile medium 30 sample from the reactor circulation to a sample taking section 8 via the valve device 7 for further analysis. 31 32 The transplant 11 which is to be cultivated and stimulated 33

is positioned in a medial position on the bottom of the reactor. A second, smaller chamber can be situated

36 underneath the transplant 11. The flow space is supplied

with the media via the hose system 4 and can be filled with a strongly porous but thin sinter material 16. This lower chamber can be sealed off by a thin sheet of transparent glass 17 and serve as a microscopy opening for inverse 5 microscopes. 6 7 In addition to the biosensors 9 which are inserted in the bioreactor cover, the upper chamber of the bioreactor 1 also includes the mini actuator 14. This mini actuator 14 which is designed as a magnetic stamp serves as a contactless 10 pressure applicator and is controlled by the control magnets 11 12 or the coil 15. 13 Example 3 14 15 Single-chamber bioreactor schema 16 Figure 3 shows a possible form of execution of the 17 bioreactor 1 comprising a culture chamber which serves the 18 implementation of the contactless controllable mini actuator 19 14. 20 21 The bioreactor 1 which is designed as a single-chamber 22 23 bioreactor comprises a carcass and the bioreactor lock 21 which is additionally sealed by a pinch ring 20. Biosensors 24 9 are integrated in the cover construction which serves to 25 26 take on-line measurements of glucose and lactate concentrations, among others. An exactly fitting integrated 27 mini actuator 14 is situated above the transplant 11 in the 28 reactor chamber, the transplant resting on a special reactor 29 floor with an inserted transparent glass plate 17. 30 31 For the supplying of the transplant 11 with the medium, a 32 minimum of one feed and one discharge penetrate the 33 34 bioreactor 1 via Luer connectors 19. A sample taking section 8 is integrated at least one of the discharges 19 via a 3-35

way valve 6.

```
2
    Example 4
 3
    Double-chamber reactor schema
 4
    Figure 4 shows an additional form of execution of a
 5
    bioreactor 1 comprising two chambers, whereby the upper
    comprises the pressure stamp 14, the lower serving the
 7
    flowing against underneath the transplant 11. The function,
    character and requirement of the components 1, 6, 8, 9, 14,
    19-21 in this form of execution do not differ from those in
10
    the bioreactor 1 described in example 3.
11
12
    At least one feed and one discharge 19 are integrated in the
13
    upper and lower reactor chambers in order to achieve a
14
    valve-controlled flowing against in the individual chamber
15
16
    and the transplant 11.
17
    The dimension of the lower chamber is of a diameter which is
18
   smaller than that of the transplant 11. This chamber
19
    includes a flat exact-matching plate of a porous sinter
20
   material 16 which enables an inverse microscopy to be
21
   carried out through the flush glass plate 17 and the
22
23
   membrane 18 to the transplant 11 without impairment. This
   plate of a sintered material 16 in the lower reactor chamber
24
   has an additional important function in this apparatus. When
25
   the transplant 11 is subjected to mechanical load by the
26
27
   pressure stamp 14, it prevents an undesirable pressing of
   the gel-like cell construct 11 into the chamber space.
28
   Depending on the user's support matrix and its viscosity,
29
   the use of a fluid-permeable membrane 18 between the sinter
30
   material 16 and the transplant 11 is intended in order to
31
   avoid a blending of the carrier material with the sinter
32
33
   material 16.
34
   Example 5
35
36
   Design and form of execution of the mini actuator 14
```

1 Figure 5 shows the design, geometry and different forms of 2 the mini actuator 14 which slides into the reactor chamber 3 it hereby having a perfect fit (shown here in a double-5 chamber model as an example), it here asserting axial pressure forces on the transplant 11 which is lying on the floor of the reactor. This magnetic pressure applicator 14 is controlled in its 10 vertical position in the bioreactor 1 contactless by means of externally arranged control magnets 15 in accordance with 11 the invention (see Fig. 5a). An absolutely vertical 12 compression can be ensured on the one hand by medially 13 positioning the transplant 11 in the bioreactor 1. On the 14 other, an exact fit dimensioning of the pressure stamp 15 16 diameter D2 to the internal bioreactor D2 must also take place. This enables the mini actuator 14 to be inserted into 17 the bioreactor 1 without the stamp jamming or inclining. In 18 all bioreactor models, this diameter D2 is to be dimensioned 19 larger than the external diameter D1 of the transplant 11. 20 21 Figure 5b shows the characteristic design of this pressure 22 unit 14. It has an extremely powerful permanent magnet 2, 23 preferably of a neodymium-iron-boron compound which, upon 24 the existence of the slightest magnetic and electromagnetic 25 fields moves in the direction of the corresponding field. 26 27 This permanent magnet 22 is of a varnished or galvanized form and encapsulated in a biological inert synthetic 28 material - the enveloping body 23 -. This preferably 29 cylindrical enveloping body 23 with its exactly fitting 30 external diameter slides into the bioreactor cylinder with 31 32 low friction and exactly vertically. The underside of the plastic enveloping body 23 can in addition to a level 33 surface, have other organotypical negative forms as a stamp 34

surface 24 impressed on it, so as to reproduce in-vivo

adaptive positive forms (including curves, arches, etc.).

35

1 The novel actuator geometry which exists here without any 2 flow channels 33 in the enveloping body 23, also provides a pump function resulting from a cyclical magnetic field 5 generation. An upward movement of the mini activator 14 enables medium to be sucked into the reactor chamber as a result of the pressure and valve rations which exist in the bioreactor 1. A downward movement or pressure compression ion the transplant 11 results in this medium being pressed out of the bioreactor 1. 10 11 Figure 5c shows an additional example of a form of execution 12 of the mini actuator 14 which also includes a strong 13 permanent magnet 22 and an enveloping body 23 with an 14 individual stamp surface 24. This model has so-called flow 15 channels 33 at the edge of its enveloping body 23 for flow 16 optimization. This enables a medium flow of the mini 17 actuator 14 to be carried out in the bioreactor chamber, so 18 that less positioning force is required to overcome the 19 media resistance. The enveloping body 23 must have at least 20 21 3 guide projections with an exactly matching external diameter D2 in order to ensure a planar positioning of the 22 complete mini actuator 14 on the transplant 11. 23 24 Figure 5d shows a modified pressure stamp 14 which is based 25 on Figure 5b but which has an extension nosepiece 34', 26 27 designed to create a spatial distance between the permanent magnet 22 and the cell culture construct 11. The cause of 28 this distancing of the permanent magnet 22 in the upper 29 cylinder head from the transplant 11 is the minimisation of 30 any field influences on the cell cultures 11. 31 32 Figure 5e shows a mini actuator 14 based on figure 5d which 33 has at least 3 flow channels 33 and 3 guide projections with 34 35 an outside diameter D2.

```
Example 6
 1
    Schema showing the construct manufacture and seeding of the
 2
   construct in the bioreactor 1
 4
 5
   Figure 6 shows the process and the equipment for
   manufacturing and seeding three-dimensional, preferably
 7
   cylindrical cell matrix constructs.
 8
 9
   In figure 6a (cell matrix seeding) multiplied (see Fig. 1,
   II) or freshly isolated (see Fig. 1, III) and prepared cells
10
   12 are mixed with the biogen carrier structure 13, suspended
11
12
   to homogeneity and injected into the seeding piston 25.
   The exactly fitting seeding piston 25 has an internal
13
   diameter D1 which corresponds to the future external
14
   diameter of the transplant 11 and an external diameter D2
15
   which corresponds to an internal diameter of the bioreactor
16
   1.
17
18
19
   Figure 6b (stamp insert) shows the stamp insert 26 in the
20
   seeding piston 25. The exactly fitting planar stamp 26 with
   the outside diameter D1 is inserted in the hollow piston
21
   cylinder on the level sliding plate 27 during the hardening
22
   out or polymerisation of the corresponding cell matrix in
23
   the reactor piston 25.
24
25
   The underside of this stamp 26 can be embossed with
26
   organotypical structures analogous to the stamp surfaces 24
27
28
   of the mini actuator 14.
29
   Figure 6c (stamp application) shows the application of the
30
   stamp 26 on the transplant 11 in the seeding piston 25. The
31
32
   stamp 26 is placed on the cell frame with a slight assertion
33
   of application pressure in order to counteract a meniscus
   formation or curving of the upper side of the matrix of the
34
   transplant 11, in order to obtain a cylindrical transplant
35
   form, etc.
36
```

```
1
    If an in-vivo adaptive surface is to be impressed on the
 2
    transplant 11, this stamp application 26 must take place
    during the hardening out or polymerization phase
    respectively.
 5
    In Figure 6d (removing the sliding plate), the applied stamp
 7
    26 is raised after the forming of the transplant 11 and the
    sliding plate 27 which should be preferably hydrophobic and
    is situated at the bottom of the seed piston is removed. In
10
    order to prevent a gel-type cell construct 11 adhering to
11
    the sliding plate 27 and the seeding piston, and inert foil
12
    or inert polymer fleece for example are used to line the
13
    surface.
14
15
    Figure 6e (construct seeding in the bioreactor) shows the
16
    seed of a cylindrical construct, taking the double-chamber
17
   bioreactor as an example. Hereby, the exactly matching
18
   seeding piston 25 is implemented in the bioreactor 1, the
19
   cell construct then being positioned medially in the
20
   prepared reactor by mean of the pressure stamp 26, the
21
22
   seeding device then being removed from the bioreactor 1.
   This prepared bioreactor 1 contains the porous sinter
23
   material 16 and a diffusion-permeable membrane 18, if
24
25
   required.
26
27
   Example 7
28
   Schema showing the technical equipment for construct
   perfusion and media blending in a single-chamber bioreactor
29
30
   Figure 7 shows the design and construction of the single-
31
   chamber reactor carcass and its effect on the diffusion and
32
33
   perfusion in transplant 11.
34
```

In the form of execution shown in Figure 7a, four feeds and discharges with an integrated Luer connector 19 run into the

- bioreactor 1. Both their locations and positions can differ in order to optimize the flow, this therefore meaning that they can also enter the bioreactor carcass tangentially. A minimum of two feeds or discharges respectively enter the bioreactor 1. A sample taking section 8 can be installed at each discharging Luer connection 19 by means of a 3-way valve 6, for example. 7 8 A static cultivation method in the bioreactor especially results in a diffusion of the media in the upper and side 10 edge areas of the cylindrical tissue transplant 11, for 11 example and provides the cell culture with nutrients, among 12 others whilst simultaneously transporting metabolic end 13 products from the carrier matrix. 14 15 Figure 7b shows a continuous feed of the culture medium from 16 the medium reservoir 2 with the optional supplement 17 18 reservoir 3 (not shown) behind it. The culture medium enters the bioreactor 1 through a minimum of one feed 19 after 19 20 passing through the hose system 4 by means of a circulation pump 5 which is capable of apportioning. 21 22 23 The medium is discharged via a minimum of one discharge 19, where it enters the hose system 4 which enables a separate 24 sample taking section 8 to be integrated at least one 25 26 position by means of a 3-way valve 6. 27 The used medium can remain in the circulation as shown here, 28 in that it enters the medium reservoir 2, from where it is 29 extracted for a repeated continuous perfusion of the 30 transplant 11. It can also be completely removed from the 31 circulation. The transplant 11 is then cultivated by means 32 of a batch or fed-batch process respectively. 33
- 35 A targeted continual feeding of the culture medium into the 36 reactor chamber can result in a clear approach and through

- 1 flowing of the transplant 11, when compared with the static
- 2 schema shown in Figure 7a. The induced perfusion results in
- 3 deeper construct regions being thoroughly rinsed with the
- 4 medium. This results in an optimization of the material
- 5 exchange and in turn, an increased cell differentiation.
- 6 This version of the construct approach flow exercises
- 7 shearing force stimulation on the embedded cells.

- 9 Example 8
- 10 Schema showing the technical equipment for construct
- 11 perfusion and media blending in a double-chamber reactor

12

- 13 Figure 8 shows a double-chamber bioreactor which permits an
- 14 optimized flow, diffusion and perfusion of the transplant,
- 15 thereby helping to improve the quality of the replacement
- 16 tissue.

17

- 18 A version with static cultivation and diffusion is shown in
- 19 Figure 8a. The feeds or discharges 19 respectively which run
- 20 into the bioreactor 1 number two as a minimum, whereby at
- 21 least one of them must run into the lower and the upper
- 22 reactor chamber. The positions, locations and densities of
- 23 the two feeds or discharges 19 shown here for each chamber
- 24 can differ in order to achieve a flow optimization.

25

- 26 The sample taking section 8 can be connected to any of the
- 27 discharge oriented Luer connections 19 in both of the
- 28 chambers by means of a 3-way valve 6, or similar.

- 30 In addition to a media diffusion of he upper and side
- 31 transplant areas, the chamber in this design which have been
- 32 set-up for the first time results in a diffusion of the
- 33 culture medium from the porous sinter material in the region
- 34 close to the floor of the carrier structure, the diffusion
- 35 being underneath the transplant 11 during the static
- 36 cultivation, this resulting in an improved metabolism

throughout the transplant 11. 2 Figure 8b shows a continuous feed of the culture medium from the medium reservoir 2 with the optional supplement 5 reservoir 3 (not shown) behind it. The culture medium enters the upper and lower chambers of the bioreactor 1 through a minimum of one feed 19 after passing thorough the hose system 4 by means of a circulation pump 5 which is capable of apportioning. 10 The medium is discharged via a minimum of one discharge 19 11 per chamber, where it enters the hose system 4 which enables 12 a separate sample taking section 8 to be integrated at least 13 one position by means of a 3-way valve 6. 14 15 The used medium can remain in the circulation as shown here, 16 17 in that it enters the medium reservoir 2, from where it is extracted for a repeated continuous perfusion of the 18 transplant 11. It can also be completely removed from the 19 circulation. The transplant 11 is then cultivated by means 20 of a batch or fed-batch process respectively. 21 22 The integration of a second chamber in the invention, shown 23 here as being underneath the transplant 11, especially shows 24 its positive feature in a targeted approach flowing of the 25 biological construct. If the media flow from media reservoir 26 2 is switched to the lower chamber by means of the 3-way 27 valve 6, an induced upwards-oriented perfusion of the 28 transplant 11 takes place whilst the lower discharge is 29 closed due to the medium only being able to leave the 30

31 32

Analogous to this schema, a switching over of the 3-way
valve 6 results in a transplant through-flow from the upper
to the lower chamber through the construct 11. The

reactor chamber via the upper discharge.

36 arrangement described here results not only in a complete

perfusion, but also in an additional cell stimulation via an induced shearing force which is asserted on the cells and can be adjusted via the volume flow of the circulation pump 5. A partial or complete opening of the 3-way valve 6 is 4 also possible in order to achieve a faster medium exchange in the bioreactor 1. 7 8 Example 9 Schema showing the fixation of the transplant 11 in the 10 bioreactor 1 11 Figures 9 are schemas showing the fixation of the transplant 12 13 11 in bioreactor 1, irrespective of whether it is the single-chamber or the double-chamber version. 14 15 Figure 9a shows the transplant which is to be stimulated 11 16 which is medially fixated above the transparent glass 17 in 17 the single-chamber bioreactor 1. With a minimum of 3 of 18 these fixation walls 28, a horizontal movement of the 19 transplant 11 on the reactor floor as a result of the 20 incoming medium flow should avoided in order to enable an 21 optimal perfusion and pressure stimulation. These 22 biocompatible fixation walls 28 which are inserted in the 23 reactor 1 must be of a height which is lower than the 24 pressure amplitude which is to be applied to the transplant 25 26 11. 27 Figure 9b shows the use of at least 3 of these fixation 28 walls 28 in a double-chamber bioreactor in order to achieve 29 a horizontal fixation of the transplant 11 in diverse flow 30 situations, thereby enabling an ideal vertical perfusion and 31 a mechanical pressure application to take place. 32 33

34 Example 10

35 Magnet systems for controlling the mini actuator 14

```
Figures 10 show characteristic devices and apparatus
    arrangement (shown in a single-chamber bioreactor) for a
    contactless controllable stimulation process for the mini
    actuator 14 on the transplant 11.
 5
 6
    Figure 10 (magnetic control effect - magnet attraction)
    shows the characteristic arrangement and principle of the
 7
    contactless controlling of the magnetic mini actuator 14 in
    the bioreactor 1 for the pressure deformation of the
    transplant 11. The alignment of the permanent magnets in the
10
   mini actuator 14 is carried out in accordance with the
11
12
    predominant magnetic field direction which is generated by
13
    externally situated control magnets 15. These control
   magnets 15 which is at least a permanent magnet or at least
14
    a coil generates a defined (electro-)magnetic field which
15
   protrudes into the complete bioreactor chamber 1 with its
16
    field lines and triggers a field direction-related movement
17
   of the mini actuator 14 pressure stamp. In the example shown
18
   in Figure 10a, the control magnets 15 show the principle of
19
   the magnet attraction, taking an arrangement from above as
20
   an example.
21
22
23
   In the example execution shown in Figure 10b (magnetic
   control effect - pushing off of the magnet) the pushing off
24
   of the magnet represents the second magnetic control effect
25
   between the magnetic control system 15 and the mini actuator
26
27
   14. A changing of the magnetic field direction of the
   control magnets 15 results in an alteration of the direction
28
   of movement of the mini actuator 14 which is now steered in
29
   the direction of the transplant 11 with an upwards
30
   orientation. By increasing the performance or magnetic flow
31
   density from the control magnets 15, the pressure load
32
   applied to the transplant 11 is increased until it reaches
33
   the target value of the in-vivo adaptive stimulation.
34
35
   The figures 10c-10e show arrangements of control elements
36
```

which can be used to steer the mini actuator 14 in a selfcontained bioreactor 1 in a cyclic manner and with a high frequency. 4 Figure 10c (controlling the mini actuator 14 by means of a 5 6 control magnet guide plate) shows a form of execution of a 7 permanent magnetic control system. In this magnetic field version, an arrangement of numerous permanent magnets 32 of 8 various sizes and with various polarities and therefore field strengths and directions works on a linear-controlled 10 guide plate 31, this being shown here as being positioned 11 12 above the reactor prototype as an example. 13 Hereby, a linear motor 29 drives a guide rail 30 with the 14 permanent magnets 32 which are situated in the magnet holder 15 31. This mobile phase of the magnet system renders a 16 movement of the bioreactor 1 unnecessary. 17 18 The control system in Figure 10d (controlling the mini 19 actuator 14 by means of rotating permanent magnets) is also 20 based on a controlling of the magnetic pressure stamp 14 by 21 means of an arrangement of permanent magnets on a rotating 22 23 disk. 24 Hereby, a servomotor 29 drives a magnet holder 31 containing 25 26 adapted permanent magnets 32 with alternating polarities. This rotating magnet holder can include four alternating 27 polarized magnets 32 and as a result they bring about a full 28 rotation of two complete pressure applications to the 29 transplant 11. The combination of this occupancy of the 30 rotating discs with magnets and the rotary speed of the 31 servomotor 29 produce a magnetic field alteration with a 32 greater frequency and therefore a highly dynamic stimulation 33

the magnet effects on the rotation system clear, taking two bioreactors 1 as an example. The form of execution of this

34

pattern on the transplant 11. The front view makes both of

```
arrangement is suitable for numerous bioreactors 1 as long
    as these can be exactly positioned above or underneath the
    centre of the control magnet.
    Figure 10e (controlling the mini actuator 14 by means of an
 5
    iron core coil 35) shows a magnet device based on a coil
 7
    arrangement.
 8
    This magnet coil system works with an induction coil 35,
 9
    which is fixated above the bioreactor 1 with generation of a
10
    defined electromagnetic field which can be invariably
11
    adjusted via the supplied electrical power, thereby enabling
12
    the mini actuator 14 to be positioned anywhere in the
13
    bioreactor carcass. A pole reversal of the direction of
14
    current results in a reversal of the existing field
15
    direction and the electromagnetic effect. The used iron core
16
    coils 35 generates its electrical field vertical to the coil
17
    winding and has both an attracting and push off effect on
18
   the static permanent magnets of the mini actuator 14.
19
20
   An automated station of this system comprises a powerful
21
   coil 35 with a low heat generation and a connected
22
   adjustable transformer, the capacity of which being
23
   monitored by a multimeter measuring device. Furthermore, the
24
   use of a microcontroller triggers a relay which switches the
25
   current in the required direction, ensuring the required
26
   effect of an intermittent pressure application to the cell
27
28
   construct.
29
   Example 11
30
   Stimulation schema in a double-chamber reactor
31
32
   Figures 11 show the complete stimulation schema of the novel
33
   GMP-conform bioreactor 1. Hereby, the mechanical pressure
34
   stimulation, perfusion and the shearing force-induced flow
35
```

takes place parallel in the three-dimensional transplant.

1 2 In Figure 11a (perfusion stimulation without mechanical load), a stimulation of the cell construct 11 only takes 3 4 place via a targeted approach flow of the media, resulting in a construct perfusion with an assertion of the shearing 5 force in a  $\mu$ Pa-range. This process example shows a 6 continuous feeding of culture media in two feeds 19 so that 7 a supply is provided to each of the reactor chambers 8 initially adjusts itself to a concentration equalization in transplant 11 and thereafter generates an upper and a lower 10 perfusion zone on the construct in relation to the selected 11 volume flows. This used medium leaves the reactor chamber 12 via two additional discharges 19. No pressure is applied 13 during this flow stimulation as the pressure stamp 14 is 14 held in a higher position in the bioreactor 1 by the control 15 16 magnet system 15. 17 In Figure 11b (perfusion stimulation and stamp application) 18 19 shows the second step which is a multiple stimulation of replacement tissue materials 11 in the bioreactor 1. As is 20 21 shown in this example, the flow conditions are initially modified. Via the 3-way valve 6, the culture medium flow is 22 23 only fed into the lower reactor chamber, from where it is perfused through the transplant 11, the material exchange 24 induced and it can then leave the upper reactor chamber via 25 26 a discharge. By reversing the poles of the control magnet 27 system, this being an iron core coil 35 with a low power 28 induction in this case, the magnetic mini actuator 14 is placed on the cylindrical replacement tissue 11, for 29 example. This stamp placement with a 0% construct 30 deformation marks a return point of the mini actuator 14 31 32 with a dynamically high-frequency deformation of the cell matrix 11. 33 34 In the next step of the stimulation process, the magnetic 35

field strength generated by the coil 35 is increased as

- shown in Figure 11c (perfusion stimulation and mechanical load). The result of this increased magnetic flow density is an increased compression of the transplant 11 to the required target deformation which preferably imitates process which is similar to in-vivo processes. After this pressure stimulation has been carried out, a change can be made between cell stimulation and stamp application in an intermittent manner.

  A static compression of the replacement material is also
- possible with the cited apparatus and the described process.

  During this mechanical load, a targeted construct perfusion

  can be inserted through the carrier matrix which supplies

  the cells with the required nutrients and metabolites

  removed which are especially exchanged, e.g. during the

  proliferation and differentiation (extracellular matrix

  synthesis).
- 19 After the pressure load protocol has been worked off, one 20 returns the stamp device back to the starting position, 21 continues to perfuse the cell culture continuously, for 22 example and removes the transplant 11 if the extracellular 23 matrix has been sufficiently synthesized, for example.

18